Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression

[1]  P. Nowak‐Sliwinska.  Optimization for multidrug combinations: Challenges and perspectives in complex disorders. , 2020, Pharmacological research.

[2]  Marchien G. Dallinga,et al.  IGF2 and IGF1R identified as novel tip cell genes in primary microvascular endothelial cell monolayers , 2018, Angiogenesis.

[3]  Robert J. Griffin,et al.  Consensus guidelines for the use and interpretation of angiogenesis assays , 2018, Angiogenesis.

[4]  U. K. Abdul,et al.  Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity , 2017, Scientific Reports.

[5]  M. Boutros,et al.  Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization. , 2016, Cancer research.

[6]  Cheng-Zhong Zhang,et al.  Chromothripsis: A New Mechanism for Rapid Karyotype Evolution. , 2015, Annual review of genetics.

[7]  Stefan W. Hell,et al.  SiR–Hoechst is a far-red DNA stain for live-cell nanoscopy , 2015, Nature Communications.

[8]  A. Griffioen,et al.  The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy , 2015, Pharmacological Reviews.

[9]  B. Slotman,et al.  Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction , 2015, Cancer medicine.

[10]  U. K. Abdul,et al.  The emerging quest for the optimal angiostatic combination therapy. , 2014, Biochemical Society transactions.

[11]  Henry Pinkard,et al.  Advanced methods of microscope control using μManager software. , 2014, Journal of biological methods.

[12]  Patrycja Nowak-Sliwinska,et al.  The chicken chorioallantoic membrane model in biology, medicine and bioengineering , 2014, Angiogenesis.

[13]  J. Kuriyan,et al.  Crenolanib is a selective type I pan-FLT3 inhibitor , 2014, Proceedings of the National Academy of Sciences.

[14]  M. Levis,et al.  Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. , 2014, Blood.

[15]  R. Milner,et al.  A novel and simple method for culturing pericytes from mouse brain. , 2012, Microvascular research.

[16]  B. Lovisa,et al.  Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion , 2012, Journal of cellular and molecular medicine.

[17]  A. Griffioen,et al.  CD34 marks angiogenic tip cells in human vascular endothelial cell cultures , 2012, Angiogenesis.

[18]  Amber N. Stratman,et al.  Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. , 2009, Blood.

[19]  K. Pierce,et al.  Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Verin,et al.  The role of cytoskeleton in the regulation of vascular endothelial barrier function. , 2008, Microvascular research.

[21]  Johanna Andrae,et al.  Role of platelet-derived growth factors in physiology and medicine. , 2008, Genes & development.

[22]  A. Griffioen,et al.  Angiogenic profiling and comparison of immortalized endothelial cells for functional genomics. , 2008, Experimental cell research.

[23]  R. Mahfouz,et al.  Understanding the biology of angiogenesis: review of the most important molecular mechanisms. , 2007, Blood cells, molecules & diseases.

[24]  Steven Song,et al.  The role of pericytes in blood-vessel formation and maintenance. , 2005, Neuro-oncology.

[25]  Viji M. Draviam,et al.  Timing and checkpoints in the regulation of mitotic progression. , 2004, Developmental cell.

[26]  C. Betsholtz,et al.  Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. , 2003, The Journal of clinical investigation.

[27]  L. Benjamin,et al.  Angiogenesis: Tumorigenesis and the angiogenic switch , 2003, Nature Reviews Cancer.

[28]  A. Griffioen,et al.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.

[29]  A. Griffioen,et al.  Examination of the role of galectins and galectin inhibitors in endothelial cell biology. , 2015, Methods in molecular biology.

[30]  T. Stevens,et al.  The actin cytoskeleton in endothelial cell phenotypes. , 2009, Microvascular research.

[31]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[32]  T. Rapoport,et al.  JCB Article , 2001 .